Advanced Solid Tumor or Hematologic Tumor
Conditions
Brief summary
This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3454 tablets in subjects with advanced solid tumor or hematologic tumor.
Interventions
DRUGTQB3454
TQB3454 tablets is a small molecule oral drug.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
\- 1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; Life expectancy ≥12 weeks. 2\. Advanced solid tumors or hematological malignancy. 3. Adequate laboratory indicators. 4. No pregnant or breastfeeding women, and a negative pregnancy test. 5. Understood and Signed an informed consent form.
Exclusion criteria
* 1\. Has central nervous system metastasis or system leukemia. 2.Previous anti-tumor treatment: 1. Has received IDH1 mutation inhibitor. 2. Has received systemic anti-tumor therapy or radiotherapy within 14 days before the first dose. 3. Has received oral targeted drugs, less than 5 drug half-lives from first dose. 4. The related toxicity of previous anti-tumor therapy has not recovered to CTCAE ≤ grade 2, except for hair loss. 3.Complicated disease and medical history: <!-- --> 1. Active hepatitis B or hepatitis C. 2. Abnormal kidney. 3. Abnormal cardiovascular and cerebrovascular. 4. Abnormal gastrointestinal. 5. Has medical history of immunodeficiency. 6. Has bleeding (hemoptysis), coagulopathy, or been using warfarin, aspirin, and other antiplatelet agglutination drugs. 7. Has uncontrollable systemic bacterial, fungal or viral active infections. 8. Has medical history of idiopathic pulmonary fibrosis,or tissue pneumonia. 9. Has allergic constitution or previous severe allergy; or known allergy to ingredients of study drug. 10. Has neurological or mental disorders. 11. Has a history of drug abuse or drug addict. 12. Has received major surgery, open biopsy, or obvious traumatic injury within 4 weeks before the first dose. 13. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study. 4\. Has participated in other clinical trials within 30 days before participating in this trial. 5\. Female patients during pregnancy or lactation. 6. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study. 7\. criteria for solid tumors: <!-- --> 1. Has any signs of bleeding constitution. 2. Has any CTCAE ≥ grade 3 bleeding or bleeding event,within 4 weeks before the first dose. 3. Has unhealed wounds, fractures, active ulcers of the stomach and duodenum, ulcerative colitis and other digestive tract diseases. 4. Imaging (CT or MRI) shows that the tumor has invaded the circumference of important blood vessels. 5. Has uncontrollable pleural effusion, pericardial effusion or ascites that still need repeated drainage. criteria for blood tumor: a) Has severe life-threatening leukemia complications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (MTD) | Baseline up to 28 days | MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tmax | Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose; | To characterize the pharmacokinetics of TQB3454 by assessment of time to reach maximum plasma concentration. |
| AUC0-t | Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose; | To characterize the pharmacokinetics of TQB3454 by assessment of area under the plasma concentration time curve from zero to infinity. |
| Cmax | Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose; | Cmax is the maximum plasma concentration of TQB3454 or metabolite(s). |
| Progression-free survival (PFS) | Up to 60 weeks | PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause. |
| 2-hydroxyglutaric acid | Hour 0(pre-dose) on single dose; Hour 0(pre-dose) of day1, day8, day15, day28 on multiple dose of first cycle; hour 0(pre-dose) of day15, day28 of second and third cycle; hour 0(pre-dose) of day28 of fourth to eighth cycle.Each cycle is 28 days. | Correlation between 2-hydroxyglutaric acid and efficacy |
| Objective response rate (ORR) | up to 60 weeks | Percentage of participants achieving complete response (CR) and partial response (PR). |
Countries
China
Contacts
Primary ContactLin Shen, Doctor
Outcome results
None listed